Business Wire

VERACODE

28.7.2022 08:52:11 CEST | Business Wire | Press release

Share
Veracode Expands Platform Capabilities in its EU-Resident Platform

Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform in Europe. Companies can now secure their software across the entire software development lifecycle (SDLC) with the added capabilities of dynamic analysis and API scanning, complementing Veracode’s static analysis, software composition analysis and manual penetration testing tools. The Veracode European Region , a cloud-based instance, allows customer data to stay resident in the EU to meet policy requirements for cloud computing.

Demand for a SaaS-based software security solution that supports data residency has never been greater. With a 20x increase * in security scanning cadence over the past decade, organisations are now testing apps for flaws more thoroughly than ever. Many are shifting further left and combining static, dynamic, and software composition analysis to gain a comprehensive view of risk and compliance to policies.

Veracode’s EMEA Chief Technology Officer, John Smith, said, “The European market has a growing need to consolidate and automate application security, while meeting stringent data residency requirements. The options for achieving this at scale are limited and complex: on-premise solutions require a large, upfront investment and frequent upgrades, while other SaaS platforms are often a pared-down version of existing on-premise products. Veracode’s cloud-native platform helps customers keep costs down and increase efficiencies by integrating multiple software security tools into one easy-to-use solution that also monitors policy compliance.”

Based in Frankfurt, Germany, the Veracode European Region is a cloud-based instance that offers customers in EMEA a broad suite of solutions as part of its unified Continuous Software Security Platform, which bridges the gap between security and development teams. Dynamic analysis and API scanning are the latest capabilities to be made available in the market. The integrated platform is unique since it gives customers a “single pane of glass” view of security posture across their entire SDLC.

Seamlessly embedded into the environments where developers work, Veracode creates a frictionless experience for developers to code securely without compromising speed of delivery. This is paramount to help businesses keep pace with accelerating deployment times, as well as to provide a comprehensive view of risk, remediation guidance, peer benchmarking, and rich analytics throughout the development pipeline.

Powered by nearly two decades of aggregate data, the cloud-native platform continually finetunes itself to improve accuracy, yielding impressively low false-positive rates. It also streamlines workflows by running daily updates of the vulnerability database, so customers are immediately apprised of any potential threats.

A customer of Veracode, a European commerce body, said, “The privacy and protection of our customers is our highest priority, so we need to be confident in our software security programme. Veracode gives us this assurance with a fully SaaS platform that is resident in the EU. Initially, we needed an automated dynamic analysis product that could crawl our applications at scale but wanted to avoid the pain of amassing several disparate tools over time. With Veracode, we are safe in the knowledge that we can leverage multiple solutions in one place as we continue to shift security further left.”

Find out more about Veracode’s European Region here .

*Veracode State of Software Security Report v12, February 2022

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.

Learn more at www.veracode.com , on the Veracode blog and on Twitter .

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/VeracodeInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release

Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic

An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal

Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release

Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve

Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release

The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value

Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release

Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye